Moomoo AIのまとめ
Mangoceuticals reported Q2 2024 revenue of $163,163, up 15.5% year-over-year, driven by increased digital marketing efforts and recurring customer subscriptions. Gross profit was $69,792, down from $87,130 in Q2 2023 due to higher shipping costs and promotional discounts. Cost of revenues increased to $93,371 from $54,107 last year, correlating with higher product sales.Operating expenses totaled $2.24 million, with significant investments in legal fees of $165,368, software development of $239,520, and stock-based compensation of $859,380. Marketing expenses decreased to $229,244 from $797,263 last year as the company optimized its advertising strategy. General and administrative expenses rose to $850,704 from $567,655 in Q2 2023.The company ended the quarter with $490,243 in cash and reported a net loss of $2.39 million compared to $2.28 million in Q2 2023. Management secured additional funding through preferred stock offerings and equity purchase agreements to support operations and growth initiatives. The company also acquired key patents related to infection prevention technologies for $20 million through a combination of preferred stock and cash payments.
Mangoceuticals reported Q2 2024 revenue of $163,163, up 15.5% year-over-year, driven by increased digital marketing efforts and recurring customer subscriptions. Gross profit was $69,792, down from $87,130 in Q2 2023 due to higher shipping costs and promotional discounts. Cost of revenues increased to $93,371 from $54,107 last year, correlating with higher product sales.Operating expenses totaled $2.24 million, with significant investments in legal fees of $165,368, software development of $239,520, and stock-based compensation of $859,380. Marketing expenses decreased to $229,244 from $797,263 last year as the company optimized its advertising strategy. General and administrative expenses rose to $850,704 from $567,655 in Q2 2023.The company ended the quarter with $490,243 in cash and reported a net loss of $2.39 million compared to $2.28 million in Q2 2023. Management secured additional funding through preferred stock offerings and equity purchase agreements to support operations and growth initiatives. The company also acquired key patents related to infection prevention technologies for $20 million through a combination of preferred stock and cash payments.
Mangoceuticalsは2024年第2四半期の売上高が163,163ドルで、前年比15.5%の増加を報告しました。これはデジタルマーケティング活動の強化と常連顧客のサブスクリプションの増加によるものです。粗利益は69,792ドルで、2023年第2四半期の87,130ドルから減少し、これは運送料とプロモーション割引の増加によるものです。売上原価は昨年の54,107ドルから93,371ドルに増加し、これは製品販売の増加と相関しています。営業費用は224万ドルに達し、法的手数料165,368ドル、ソフトウェア開発239,520ドル、株式ベースの報酬859,380ドルに大きく投資しました。マーケ...すべて展開
Mangoceuticalsは2024年第2四半期の売上高が163,163ドルで、前年比15.5%の増加を報告しました。これはデジタルマーケティング活動の強化と常連顧客のサブスクリプションの増加によるものです。粗利益は69,792ドルで、2023年第2四半期の87,130ドルから減少し、これは運送料とプロモーション割引の増加によるものです。売上原価は昨年の54,107ドルから93,371ドルに増加し、これは製品販売の増加と相関しています。営業費用は224万ドルに達し、法的手数料165,368ドル、ソフトウェア開発239,520ドル、株式ベースの報酬859,380ドルに大きく投資しました。マーケティング費用は昨年の797,263ドルから229,244ドルに減少し、これは会社が広告戦略を最適化したためです。一般および管理費用は2023年第2四半期の567,655ドルから850,704ドルに増加しました。会社は四半期の終わりに490,243ドルの現金を持ち、2023年第2四半期の228万ドルと比較して239万ドルの純損失を報告しました。経営陣は業務と成長戦略を支援するために、優先株公募と株式購入契約を通じて追加の資金を確保しました。会社はまた、優先株と現金支払いの組み合わせを通じて、感染予防技術に関連する主要な特許を2,000万ドルで取得しました。
役に立った
役に立たない
